Category: News

deutraMed Biomolecule Stabilization Technology Platform Earns Additional Patent, Opening Door to New Biomedical Applications

Posted on

Patented new value-added method improves mRNA stability during synthesis and storage

(Collingwood, Ont., July 19, 2023) – deutraMed Inc. today announced that its Biomolecule Stabilization Technology Platform has been awarded an additional patent related to mRNA stabilization. The patented solution improves mRNA stability during synthesis and storage, decreasing the significant cost and challenge of cold-chain logistics.

“deutraMed’s Biomolecule Stabilization Technology Platform provides a versatile foundation for the stabilization of a broad array of biomedical applications,” says Lisa Stuart, Managing Director of deutraMed Inc. “Our ongoing scientific research program is advancing diverse applications of the platform, supported by a world-class Scientific Advisory Board.”

The company’s mRNA stabilization application, named D-Lock™, shows promise in enabling the distribution of mRNA-based medical treatments in settings where it would not be practical due to the inherent instability of the medicines themselves. Utilizing the company’s BioPure Deuterium Oxide™ product, the platform stabilizes certain active pharmaceutical ingredients to enable longer-term transportation and storage at refrigerator temperatures.

“We are proud of our progress in helping to make mRNA therapeutics more practical and affordable by lowering the barrier of cold chain logistics,” Stuart says. “D-Lock™ shows great potential to make mRNA storage and distribution more practical, especially in remote locations with poor infrastructure.”

Beyond stabilization, mRNA synthesis using D-Lock™ technology significantly improves both transcription and translation efficiency compared with conventional in vitro transcription technology.

Translation refers to the process by which a protein is synthesized from information contained in an mRNA molecule. Transcription is the process by which the genetic information in a strand of DNA is copied into a new molecule of mRNA.

What is mRNA and why is it important?

Messenger RNA (mRNA) is a type of RNA that is required for protein production. It differs from DNA, which stores the genetic information in our bodies; mRNA carries the information that directs cells to produce proteins.

mRNA is the foundation of many new advanced therapeutics where stabilization can offer significant potential benefits. These include treatments currently in development and undergoing clinical trials for diabetes, cancer, cardiovascular diseases, infectious diseases and other medical conditions. In the case of vaccines, mRNA codes for the proteins that trigger an immune response helping to protect against diseases such as COVID-19.

mRNA is inherently unstable. It is susceptible to both thermal and enzymatic degradation. This degradation is a temperature-dependent process: higher temperatures will lead to more degradation. Even at refrigerated temperatures of 4°C, mRNA integrity may only be maintained for a short period of time. As a result, -80°C freezers are often required to preserve the integrity of mRNA therapeutics.

deutraMed to Attend mRNA-Based Therapeutics Summit; Chief Scientist to Present Research Findings

deutraMed Managing Director Lisa Stuart and the company’s Chief Scientist, Dr. Pavel Gris, will attend the July 26-28, 2023 mRNA-Based Therapeutics Summit in Boston. Dr. Gris, PhD, MRSC, C. Chem. and an Adjunct Professor in University of Waterloo’s Department of Chemistry, will present research findings on the company’s “D-Lock™” technology at a poster session during the Summit.

To arrange an on-site meeting with deutraMed’s representatives, please email sales@deutramed.com or call 1 (833) 338-8726. The mRNA Summit focuses on advancements, opportunities and challenges related to mRNA-based therapeutics and vaccines. For more information on the Summit, visit: www.mrnabased-therapeutics.com.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from deutraMed’s world-class Scientific Advisory Board. deutraMed is a member of the Key DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth

Phone: 416-565-8920

Email: don.hogarth@deutramed.com

To view the press release, visit: deutraMed Biomolecule Stabilization Technology Platform Earns Additional Patent, Opening Door to New Biomedical Applications (yahoo.com)

deutraMed to Attend mRNA-Based Therapeutics Summit; Chief Scientist to Present Research Findings

Posted on

July 26-28, 2023

Boston, MA

deutraMed Managing Director Lisa Stuart and the company’s Chief Scientist, Dr. Pavel Gris, will attend the July 26-28, 2023 mRNA-Based Therapeutics Summit in Boston.

Dr. Gris, PhD, MRSC, C. Chem. and an Adjunct Professor in University of Waterloo’s Department of Chemistry, will present research findings on the company’s patented mRNA stabilization technology, which stabilizes mRNA therapeutics for transportation and enhances their production.

The technology, named “D-Lock™”, is designed to mitigate the inherent instability of mRNA therapeutics, and thereby overcome the significant cost and challenge of cold-chain logistics. In addition, mRNA synthesis using D-Lock™ significantly improves both transcription and translation efficiency compared with conventional in vitro technology.

To arrange an on-site meeting with deutraMed’s representatives, please email sales@deutramed.com or call 1 (833) 338-8726. The Summit focuses on advancements, opportunities and challenges related to mRNA-based therapeutics and vaccines. For more information on the Summit, visit: www.mrnabased-therapeutics.com.

Hudson Gibbs Wins deutraMed Chemistry and Innovation Award at Canada-Wide Science Fair

Posted on

(Collingwood, Ont., May 24, 2023) – deutraMed Inc., a breakthrough deuterium science and innovation company, congratulates Hudson Gibbs, a Grade 7 student from Cornwall, Ontario, for winning the deutraMed-sponsored Chemistry and Innovation Award at the 2023 Canada-Wide Science Fair (CWSF).

Gibbs, an Iona Academy Catholic School student, won the award for his project “Wait! The Juice Trucks are Out?” in the science fair’s grade 7 and 8 Junior Category. He was looking for an alternative solution to de-icing roads that would avoid the ecological damage caused by salt accumulation in soil and ponds. He was first inspired by a news clipping about Cornwall’s use of beet juice to keep the city’s roads ice-free while reducing salt use.

Gibbs demonstrated the functionality of juice as a de-icer by freezing asphalt in different juice mixtures and then testing which juice produced the most significant slide resistance. He found that pickle juice had the greatest slide resistance and that juices with higher sugar content were more resistant to freezing. Gibbs’ results led him to develop pods similar to detergent pods with a mixture of pickle juice to prevent re-icing, beet juice to prevent ice from forming as it freezes, and salt, all encased in biodegradable plastic pods similar to detergent pods.

“Gibbs’ solution displays a passion for science, innovation, and thoughtful pursuit of environmental betterment through scientific progress,” said Marjo Piltonen, Director of Laboratory Services at deutraMed.“ “We are excited to offer him this award and to continue supporting young scientific minds in pursuing scientific innovation and exploration.”

The Canada-Wide Science Fair, held this year in Edmonton, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects nationwide.

deutraMed sponsors the Chemistry and Innovation award as part of its commitment to fostering Canada’s next generation of STEM innovators. The award recognizes the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry.

Gibb’s project can be viewed at https://projectboard.world/ysc/project/wait-are-the-juice-trucks-out. 

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the life sciences and high technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. deutraMed is a member of the Key DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth

Phone: 416-565-8920

Email: don.hogarth@deutramed.com

deutraMed to Attend mRNA-Based Therapeutics Summit Europe

Posted on

deutraMed to Attend mRNA-Based Therapeutics Summit Europe

January 24-26, 2023

Berlin, Germany

deutraMed Chief Scientist Dr. Pavel Gris will attend the mRNA-Based Therapeutics Summit Europe, to be held in Berlin, Germany in January 2023.

Dr. Gris, PhD, MRSC, C. Chem. and an Adjunct Professor in University of Waterloo’s Department of Chemistry, will join more than 250 leaders and scientists from academia and the pharmaceutical and biotech industries at the conference. Speakers and attendees will share updates to help advance mRNA-based vaccine and therapeutic strategies.

With the introduction of mRNA-based Covid-19 vaccines over the past few years, academics and industrial participants in this field are actively exploring the development and deployment of other mRNA-based therapies to combat diabetes, cancer, cardiovascular diseases, infectious diseases and other medical conditions.

Dr. Gris leads a team at deutraMed that has developed a proprietary method to stabilize mRNA using deuterium, based on the company’s Biomolecule Stabilization Technology platform. Initial study results demonstrate that the method can stabilize mRNA for 8+ months at refrigerator temperatures and 7+ days at room temperature. This would overcome significant cost and logistics challenges arising from the current need for ultra-cold storage and transportation of mRNA vaccines and other therapeutics.

To connect with Dr. Gris and other members of the deutraMed team, please call 1 (833) 338-8726 or send an email to sales@deutramed.com.

For more information about the conference, visit https://mrnabased-therapeutics-europe.com.

Electronic Specialty Gas (ESG) Conference and Business Interface Conference (BIC) hosted by Linx Consulting

Posted on

deutraMed to Attend Electronic Specialty Gas Conference

October 19-21, 2022

Chandler, Arizona

deutraMed will attend the Electronic Specialty Gas Conference and Business Interface Conference to be held October 19 to 21 at the Wild Horse Pass Hotel in Chandler, Arizona.

The Electronic Specialty Gas Conference, hosted by Linx Consulting, provides a forum for engagement and learning about the market, technology trends, and market drivers for specialty gases used in the electronics industry. deutraMed is a leading global supplier of deuterium gas, which is increasingly used in the manufacturing of semiconductors as well as OLED displays, fibre optics and life science applications.  

deutraMed will be represented at the conference by Rob Clark P. Eng., MBA, Vice President; Steven Bovair, Sales Manager; and Eric Pioli B. Eng., Process Engineering Lead. They will join numerous industry attendees including executives, buyers and product managers, as well as strategic planners from the electronic gases value chain including end-users, producers and equipment suppliers.

To connect with deutraMed’s conference team, please call 1 (833) 338-8726 or send an email to sales@deutramed.com.

For more information about the conferences, visit  https://www.linx-consulting.com/electronic-specialty-gas-conference.

New Brunswick Student Wins deutraMed Chemistry and Innovation Award at Canada-Wide Science Fair

Posted on

(Collingwood, Ont., May 31, 2022) – deutraMed Inc., a breakthrough deuterium science and innovation company, congratulates Grade 8 student Kevin Cornell of Riverview, New Brunswick for winning the deutraMed-sponsored Chemistry and Innovation Award at the 2022 Canada-Wide Science Fair (CWSF).

Cornell, a student at Riverview Middle School, won the award for his project, “Accessible Hydrogen Therapy with Graphite Electrodes” in the science fair’s Grade 7 and 8 Junior Category. Hydrogen therapy is an emerging medical treatment that uses hydrogen and oxygen gases to help treat arthritis, diabetes, asthma, brain injuries, Parkinson’s disease and many other conditions. It can also help suppress the growth of cancer cells, reduce chemotherapy side effects, and even help treat COVID-19.  

Cornell’s project seeks to overcome an apparent barrier to widespread adoption of this therapy – the high cost of machines used to create pure hydrogen and oxygen. His generator can create approximately 150ml per minute of mixed hydrogen and oxygen gas, and costs only $72. By comparison, he found a similar machine that produces 450ml of mixed gas per minute for a listed price of $2,355.

“The judging team unanimously agreed that the Cornell’s project demonstrated excellent research and troubleshooting skills, broad knowledge of the field, and deep interest in the topic and experiment,” said Marjo Piltonen, Director of Laboratory Services at deutraMed. “We congratulate Kevin on his accomplishment.”

The Canada-Wide Science Fair, held virtually May 16-20, 2022, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects from across the country.

deutraMed, which produces value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors, sponsors the Chemistry and Innovation award as part of its commitment to fostering Canada’s next generation of STEM innovators. The award recognizes the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry.

Cornell’s project can be viewed at https://projectboard.world/ysc/project/accessible-hydrogen-therapy-with-graphite-electrodes. It was one of six projects identified for final evaluation.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. deutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth

Phone: 416-565-8920

Email: don@hogarthpr.com

deutraMed Congratulates Dawson Creek, BC’s Tyson Neufeld on Winning Canada-Wide Science Fair Chemistry Award

Posted on

(Collingwood, Ont., May 21, 2021) – deutraMed Inc., a breakthrough deuterium science and innovation company, today congratulated Grade 8 student Tyson Neufeld for winning the deutraMed-sponsored Chemistry and Innovation Award at the Canada-Wide Science Fair (CWSF).

Neufeld, a student at Mountain Christian School in Dawson Creek, BC, won the award in the science fair’s Grade 7 and 8 Junior Category. His project, “Microbial Fuel Cells for Improved Contaminated Soil Clean up and BioElectricity Generation”, also won the Junior Category “Energy Challenge” and separately, an award at the recent Northern BC Regional Science Fair.

“Tyson impressed me and other judging team members with his innovative thinking and excellent presentation,” said Sofia Kalil, Team Leader – Electrochemistry & Intellectual Property at deutraMed. “Congratulations on your achievement, Tyson!”

The Canada-Wide Science Fair, held virtually May 17-21, 2021, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects from across the country. The Chemistry and Innovation Award recognizes the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry.

deutraMed, which produces value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors, sponsored the award as part of its commitment to fostering Canada’s next generation of STEM innovators and entrepreneurs.

The CWSF annually brings together Canada’s top STEM talent at the middle and high school levels. According to the Science Fair’s organizer, Youth Science Canada, every year more than 500,000 young Canadians participate in project-based science, about the same number who are involved in minor hockey.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com

Université de Sherbrooke and deutraMed, a KEY DH Technologies’ Subsidiary, Accelerate $500,000 mRNA Vaccine Stabilization Technology Project

Posted on

Collaboration seeks to alleviate cold storage requirements for mRNA COVID vaccines, enhance other medical therapeutics

(Sherbrooke, Que. and Collingwood, Ont., May 21, 2021) – Université de Sherbrooke and KEY DH Technologies Inc. subsidiary deutraMed Inc. today announced a collaboration to accelerate the development of deutraMed’s innovative Biomolecule Stabilization Technology platform.

The $500,000 project seeks to further validate the platform’s effectiveness in stabilizing mRNA COVID vaccines and a wide range of other advanced medical therapeutics. It is supported jointly with cash and in-kind contributions from deutraMed, Universite de Sherbrooke and MITACS, a national, not-for-profit organization that works with universities, businesses, federal, and provincial governments to deliver research and training programs. 

The successful advancement of deutraMed’s stabilization platform could enable mRNA COVID vaccines to be stored and transported at higher temperatures than is possible now. This would resolve significant logistical challenges to global vaccine distribution caused by the need for storage at temperatures as low as -70 degrees Celsius.

“Université de Sherbrooke is playing a key role in our efforts to accelerate deutraMed’s Biomolecule Stabilization Technology platform,” says Andrew Stuart, President and CEO, KEY DH Technologies. “The university has the laboratory facilities and people required to do this, notably Professor Denis Gris, a well-known and respected research scientist in the fields of cellular and molecular immunology.” 

deutraMed’s stabilization platform utilizes the company’s BioPure Deuterium Oxide™ product. The platform stabilizes certain active pharmaceutical ingredients, thereby enabling medical treatments which would otherwise not be practical due to the inherent instability of the advanced medicines themselves.

mRNA is the foundation of many new advanced therapeutics where stabilization can offer significant potential benefits. These include treatments currently in development and undergoing clinical trials for diabetes, cancer, cardiovascular diseases, infectious diseases and other medical conditions.

“I am delighted to collaborate with deutraMed in its cutting-edge work on mRNA stabilization, with support from the MITACS program,” said Professor Gris, Université de Sherbrooke, Département de Pharmacologie et Physiologie. “This work will help advance an important emerging field of therapeutics.”

About KEY DH Technologies Inc.

KEY DH Technologies develops innovation-driven businesses in the deuterium and hydrogen industries, serving global markets. KEY’s three main operating companies include: Hydrogen Optimized, a private hydrogen technology company that develops and commercializes the patent-pending RuggedCell™ water electrolysis systems for the large-scale production of Green Hydrogen; Isowater®, a world-leading supplier of deuterium oxide to global customers in the life sciences, high technology and environmental science sectors; and deutraMed™, a breakthrough deuterium science and innovation company that provides clients with high-value deuterium-containing products for specialized applications along with IP-driven research and services. For more information, please visit https://keydht.com.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com

deutraMed to Sponsor Chemistry Award at Upcoming Canada-Wide Science Fair

Posted on

Company aims to encourage interest and achievement in STEM studies among young Canadians

(Collingwood, Ont., May 11, 2021) – deutraMed Inc., a breakthrough deuterium science and innovation company, today proudly announced its support for the Canada-Wide Science Fair (CWSF). The Science Fair, to be held virtually May 17-21, 2021, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects from across the country.

deutraMed, which produces value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors, is sponsoring CWSF’s Chemistry and Innovation Award for Grade 7 and 8 students. The award, to be announced on May 20, will recognize the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry. 

“deutraMed’s support for the Canada-Wide Science Fair reflects our commitment to fostering Canada’s next generation of STEM innovators and entrepreneurs,” says Lisa Stuart, Managing Director, deutraMed. “Our goal in sponsoring the Chemistry and Innovation Award is to recognize promising young STEM students for their ingenuity, determination and hard work, and to encourage them to continue on the path to becoming Canada’s future STEM leaders.” 

The winner of the Grade 7/8 CWSF Chemistry and Innovation Award will be selected by Sofia Kalil, Team Leader – Electrochemistry & Intellectual Property at deutraMed. Ms. Kalil is a Chemical Engineering student at the University of Toronto.

“As an organization based on scientific innovation, we depend on the creative talent and technical contributions of recent STEM graduates and coop students for our success,” Ms. Kalil says. “In just a few years, today’s young science fair participants will be central to the success not only of companies like ours, but also Canada’s economy.”

The CWSF annually brings together Canada’s top STEM talent at the middle and high school levels. According to the Science Fair’s organizer, Youth Science Canada, every year more than 500,000 young Canadians participate in project-based science, about the same number who are involved in minor hockey.

About deutraMed Inc. 

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com.  

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com 

                          

DEUTRAMED™ INC. ANNOUNCED PROGRESS WITH mRNA VACCINE COLD CHAIN STABILIZATION TECHNOLOGY

Posted on

DEUTRAMED™ INC. ANNOUNCED PROGRESS WITH mRNA VACCINE COLD CHAIN STABILIZATION TECHNOLOGY

Collingwood, ON, Canada – November 17th, 2020 – deutraMed™ Inc. is pleased to announce significant progress with its Biomolecule Stabilization Technology platform.  Results from recent testing provides evidence that stabilization of mRNA was achieved.  mRNA is the foundation of many new advanced therapeutics including the recently announced COVID-19 vaccines by both Moderna and pharmaceutical giant Pfizer Inc.

“The cold chain supply challenge for complex therapeutics, including vaccines, is a significant hurdle for their delivery to the global population.” Said Lisa Anne Stuart, Managing Director of deutraMed™ Inc.  “Our Biomolecule Stabilization Technology platform addresses this issue.  History has examples, such as the polio vaccine, where failed cold chain supply would inactivate the vaccine.  The rapidly growing number of mRNA-based therapeutics in the pharmaceutical industry pipeline requires solutions for successful logistics of distribution in the future.  For example, for the recently announced Pfizer mRNA-based COVID-19 vaccine, it is thought that immunization will require two doses delivered from a vaccine supply, stored and shipped at temperatures less than 70°C below zero.  The infrastructure requirements (including road, aircraft, trucking and intermodal handling) to ensure effective cold chain supply are not established for such stringent conditions. deutraMed is advancing solutions for this infrastructure which could lower cost and improve molecule distribution success as well as make it easier for people to receive effective medication.”

“The advance being announced today provides evidence of our progress to stabilize mRNA.” noted Dr. Joseph P. Porwoll, Chairman of deutraMed Inc.  “Stabilized mRNA provides foundational support for preserving bio-molecules used in medicine. I am proud of our leading deuterium experts in our Scientific Advisory Board who identified multiple deuterium technology pathways and recommended Biomolecule Stabilization as a top priority in 2019.  Clearly the impact of COVID-19 on the world has heightened the urgency of our technology and our scientists are starting to create results.”

On March 5th 2020, deutraMed™ announced the introduction of its BioPure Deuterium Oxide™ products.  This non-compendial excipient stabilizes certain active pharmaceutical ingredients (APIs).  BioPure Deuterium Oxide™ enables medical treatments which would otherwise not be practical due to the inherent instability of the advanced medicines themselves.

Deuterium use in the pharmaceutical and the life sciences industry is expanding.  Replacing protium, the most abundant isotope of hydrogen, with deuterium has enabled life science innovators to harness the deuterium isotope to their advantage.  The bond strength between deuterium and carbon is greater than protium and carbon, thus replacing light hydrogen with deuterium modifies some of the physical, chemical and biochemical properties of non-deuterated compounds. Published investigations and patents illustrate the wide range of life science possibilities for deuterated ingredients administered through skin, intermuscular, intravenous, oral, and ocular pathways.

About deutraMed™ Inc.

deutraMed™ Inc. was formed in 2017 to meet the expanding global demand for deuterium containing ingredients and deuterium expertise. Founded by a group of industry specialists, the deutraMed™ team identified the need for expertise in deuterium science and innovation to achieve a focused and reliable supply of deuterium ingredients including deuterium gas, deuterium compounds, and intellectual property driven research and services. With applications in the life sciences to high technology, deuterium ingredients are being used globally to create a healthy and connected world. It is our duty to deliver innovations in deuterium ingredients to our clients.

deutraMed™ Inc. works with customers individually, using secure deuterium supply, expertise, and premium CMO/CRO/CDMO services to advance custom deuterium innovations in parallel with strategic growth milestones.

For more information please contact:

Media Relations

Darren MacVicar
deutraMed Inc.

Email: darren.macvicar@deutramed.com
Phone: (833) 338 8726 ext 705                                                                            
40 Sandford Fleming Drive Collingwood ON, Canada L9Y 4V7